Ultragenyx Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:RARE)

15 May 2026, 15:54 by Teresa Graham · The Cerbat Gem

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) was the recipient of some unusual options trading on Friday. Traders purchased 8,880 call options on the stock. This represents an increase of approximately 864% compared to the average volume of 921 call options.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 8,135 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $185,478.00. Following the sale, the executive vice president owned 76,346 shares in the company, valued at $1,740,688.80. This represents a 9.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Theodore Alan Huizenga sold 1,632 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $37,209.60. Following the sale, the chief accounting officer owned 48,670 shares in the company, valued at approximately $1,109,676. This trade represents a 3.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 111,522 shares of company stock worth $2,543,214 over the last quarter. 5.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Entropy Technologies LP boosted its position in shares of Ultragenyx Pharmaceutical by 80.9% during the 1st quarter. Entropy Technologies LP now owns 109,727 shares of the biopharmaceutical company’s stock worth $2,299,000 after acquiring an additional 49,086 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Ultragenyx Pharmaceutical by 53.4% in the 1st quarter. Renaissance Technologies LLC now owns 561,700 shares of the biopharmaceutical company’s stock valued at $11,768,000 after purchasing an additional 195,600 shares during the period. Pale Fire Capital SE boosted its position in shares of Ultragenyx Pharmaceutical by 61.7% in the 1st quarter. Pale Fire Capital SE now owns 16,514 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 6,303 shares during the period. Knott David M Jr boosted its position in shares of Ultragenyx Pharmaceutical by 65.3% in the 1st quarter. Knott David M Jr now owns 33,069 shares of the biopharmaceutical company’s stock valued at $693,000 after purchasing an additional 13,063 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 66.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 11,050 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 4,403 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE traded down $0.70 on Friday, hitting $25.10. 751,394 shares of the company’s stock were exchanged, compared to its average volume of 2,191,961. The firm’s 50-day moving average is $23.02 and its 200 day moving average is $26.53. The company has a market capitalization of $2.47 billion, a PE ratio of -4.10 and a beta of 0.39. Ultragenyx Pharmaceutical has a 1-year low of $18.29 and a 1-year high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The business had revenue of $136.00 million for the quarter, compared to analyst estimates of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The company’s revenue was down 2.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.57) earnings per share. On average, analysts anticipate that Ultragenyx Pharmaceutical will post -4.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. HC Wainwright cut their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and cut their price target for the stock from $61.00 to $25.00 in a report on Tuesday, March 24th. Wall Street Zen downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday. JPMorgan Chase & Co. cut their price target on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a report on Thursday, March 12th. Finally, Wells Fargo & Company upped their price objective on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $60.41.

Get Our Latest Report on RARE

About Ultragenyx Pharmaceutical

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.